NewsMV
In focus for HAE: a board seat filled as of July 24, 2026, by Martin Madaus, a diagnostics and life sciences executive whose career spans more than 30 years at the C-suite level of major global health companies.
The appointment was disclosed in an 8-K filing.
What to watch next for Haemonetics Corporation (NYSE: HAE), headquartered in Boston, is how Madaus's commercial and operational background shapes board-level decisions across the company's Apheresis and MedSurg segments.
Who Martin Madaus is The breadth of Madaus's operating history covers three prior chief executive roles.
Keep reading